Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Plasma cell 1

Conditions

Sarcoma, Clear Cell 2Sarcoma 2Neurofibrosarcoma 2Nerve Sheath Neoplasms 2Liposarcoma 2Histiocytoma, Angiomatoid Fibrous 2Granuloma, Plasma Cell 2Fibrosarcoma 2Dermatofibrosarcoma 2Chondrosarcoma, Extraskeletal Myxoid 2Vascular Neoplasms 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Perivascular Epithelioid Cell Neoplasms 1Osteosarcoma 1Neoplasms, Plasma Cell 1Neoplasms, Adipose Tissue 1Myoepithelioma 1Liposarcoma, Myxoid 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Granular Cell Tumor 1Glomus Tumor 1Disorders of Sex Development 1Chondrosarcoma, Mesenchymal 1Carcinoma, Renal Cell 1

Interventions

selinexor 1repotrectinib 1pazopanib 1Suspensions 1Proton Therapy 1Ifosfamide 1Doxorubicin 1Capsules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solitary Fibrous Tumors × pazopanib × Plasma cell × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡